CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350]
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-43426AF350
Clone O323 was used by HLDA to establish CD designation.
![CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350]](https://resources.bio-techne.com/images/products/nbp1-43426af350_mouse-monoclonal-cd27-tnfrsf7-antibody-o323-alexa-fluor-350-288202315264369.jpg "CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350] [NBP1-43426AF350] -")
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Flow Cytometry
Label
Alexa Fluor 350 (Excitation = 346 nm, Emission = 442 nm)
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # O323
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Summary for CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350]
Immunogen
The immunogen for this antibody was CD27.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Scientific Data Images for CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350]
CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350] [NBP1-43426AF350] -
CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350] [NBP1-43426AF350] - Vial of Alexa Fluor 350 conjugated antibody. Alexa Fluor 350 is optimally excited at 346 nm by the UV laser (350 or 355 nm) and has an emission maximum of 442 nm.Applications for CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD27/TNFRSF7
Membrane-bound CD27 is expressed as a disulfide-linked homodimer (3). CD27 binds to the ligand CD70, a transmembrane glycoprotein that is transiently expressed on activated immune cells such as antigen presenting cells (APCs), dendritic cells (DCs), NK cells, B cells, and T cells (1,2,6,7). The receptor-ligand binding interaction leads to NFkappaB and c-Jun pathway activation which promotes immune stimulation and activation and survival of CD4+ T cells, CD8+ T cells, memory T cells, and NK cells (2,6,7). Both CD27 and CD70 are often abnormally expressed or dysregulated on malignant and cancer cells leading to immune evasion and tumor progression (7). CD27 has become a target of interest of immunotherapies for viral infections, autoimmune disease, and cancer (2). Varlilumab, an agonistic CD27 monoclonal antibody (mAB), has entered clinical trials for the treatment of hematological and solid tumor cancers (1,6). Additional clinical trials are in process that combine varlilumab with other immune checkpoint inhibitors like the programmed cell death protein-1 (PD-1) blocking mAb nivolumab (1,2). Initial results are promising, suggesting that targeting CD27, especially in combination with other therapeutics, may be a promising and effective immunotherapy for a variety of pathologies (1,2,6).
References
1. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4(Suppl 3):e000629. https://doi.org/10.1136/esmoopen-2019-000629
2. Grant EJ, Nussing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017;22:77-88. https://doi.org/10.1016/j.coviro.2016.12.001
3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. https://10.1182/blood-2017-07-741025
4. Uniprot (P26842)
5. Uniprot (P41272)
6. van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655-667. https://doi.org/10.2217/imt.15.32
7. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12. https://doi.org/10.1186/s13046-021-02215-y
Alternate Names
CD27, TNFRSF7
Gene Symbol
CD27
Additional CD27/TNFRSF7 Products
Product Documents for CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350]
Product Specific Notices for CD27/TNFRSF7 Antibody (O323) [Alexa Fluor® 350]
Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...